Olfr1095 is an olfactory receptor, specifically a member of the G protein-coupled receptor (GPCR) family. GPCR inhibitors represent a broad class of compounds that target G protein-coupled receptors, a large family of cell surface receptors essential in numerous physiological processes. These inhibitors, while not receptor-specific, can significantly influence the signaling pathways mediated by GPCRs. The signaling involves various G proteins activation, leading to downstream effects, including the modulation of adenylyl cyclase, ion channels, and cellular second messenger levels.
The inhibitors listed, such as beta-adrenergic blockers and angiotensin II receptor antagonists, operate by competitively binding to GPCRs or influencing their signaling cascades. This can indirectly affect specific olfactory receptors like Olfr1095. For example, beta-blockers like Propranolol and Timolol inhibit beta-adrenergic receptors, decreasing cyclic AMP levels, a second messenger in GPCR signaling. This decrease potentially impacts signaling pathways associated with olfactory receptors. These GPCR inhibitors have wide applications, extending beyond the olfactory system. Their indirect effects on receptors like Olfr1095 underscore the complexity of GPCR-mediated signaling. Understanding these interactions is essential for developing targeted therapies to modulate GPCR activity with greater specificity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol is a non-selective beta-adrenergic receptor antagonist. It modulates GPCR signaling pathways, potentially influencing Olfr1095 activity indirectly. | ||||||
Timolol maleate | 26921-17-5 | sc-507468 | 100 mg | $500.00 | ||
Timolol is a beta-adrenergic blocker that can affect GPCR-mediated pathways, potentially altering the signaling cascades in which Olfr1095 is involved. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Carvedilol is a non-selective beta-blocker and alpha-1 blocker. Its dual action may impact GPCR signaling, indirectly affecting Olfr1095 function. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Losartan is an angiotensin II receptor antagonist targeting GPCRs, potentially influencing pathways that indirectly modulate Olfr1095. | ||||||
Valsartan | 137862-53-4 | sc-220362 sc-220362A sc-220362B | 10 mg 100 mg 1 g | $40.00 $92.00 $122.00 | 4 | |
Valsartan, an angiotensin II receptor blocker, can affect GPCR-mediated signaling, possibly impacting Olfr1095 indirectly. | ||||||
Labetalol | 36894-69-6 | sc-484723 | 50 mg | $180.00 | ||
Labetalol, a mixed alpha/beta adrenergic antagonist, may affect GPCR signaling, potentially impacting Olfr1095 activity. | ||||||
Nadolol | 42200-33-9 | sc-253175 | 1 g | $184.00 | ||
Nadolol, a non-selective beta-blocker, influences GPCR pathways and could indirectly affect Olfr1095 signaling. | ||||||
Nebivolol | 99200-09-6 | sc-279910 | 100 mg | $803.00 | 1 | |
Nebivolol is a beta-1 blocker with effects on GPCR pathways and Olfr1095 activity due to its nitric oxide-potentiating vasodilatory effect. | ||||||
Telmisartan | 144701-48-4 | sc-204907 sc-204907A | 50 mg 100 mg | $72.00 $94.00 | 8 | |
Telmisartan, an angiotensin II receptor antagonist, might influence GPCR-mediated pathways, affecting Olfr1095 indirectly. | ||||||